Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$26.67 +3.6%	$24.58	$20.92 ▼ $34.19	$50.52B	N/A	253,389 shs	180,077 shs
LLY Eli Lilly and Company	$826.20 +1.7%	$744.36	$623.78 ▼ $935.63	$781.97B	0.47	4.07 million shs	2.35 million shs
MRK Merck & Co., Inc.	$84.11 -0.7%	$83.67	$73.31 ▼ $111.20	$210.08B	0.37	14.90 million shs	9.15 million shs
NVO Novo Nordisk A/S	$56.72 +0.1%	$55.80	$45.05 ▼ $119.07	$253.23B	0.68	12.11 million shs	8.42 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	-1.68%	-2.68%	+7.92%	+10.33%	-23.27%
LLY Eli Lilly and Company	-0.73%	-3.75%	+7.65%	+3.01%	-12.73%
MRK Merck & Co., Inc.	-0.95%	-3.21%	+2.35%	+2.88%	-22.67%
NVO Novo Nordisk A/S	-1.45%	-4.12%	+3.15%	-15.52%	-52.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$26.67 +3.6%	$24.58	$20.92 ▼ $34.19	$50.52B	N/A	253,389 shs	180,077 shs
LLY Eli Lilly and Company	$826.20 +1.7%	$744.36	$623.78 ▼ $935.63	$781.97B	0.47	4.07 million shs	2.35 million shs
MRK Merck & Co., Inc.	$84.11 -0.7%	$83.67	$73.31 ▼ $111.20	$210.08B	0.37	14.90 million shs	9.15 million shs
NVO Novo Nordisk A/S	$56.72 +0.1%	$55.80	$45.05 ▼ $119.07	$253.23B	0.68	12.11 million shs	8.42 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	-1.68%	-2.68%	+7.92%	+10.33%	-23.27%
LLY Eli Lilly and Company	-0.73%	-3.75%	+7.65%	+3.01%	-12.73%
MRK Merck & Co., Inc.	-0.95%	-3.21%	+2.35%	+2.88%	-22.67%
NVO Novo Nordisk A/S	-1.45%	-4.12%	+3.15%	-15.52%	-52.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
LLY Eli Lilly and Company	2.68	Moderate Buy	$948.06	14.75% Upside
MRK Merck & Co., Inc.	2.29	Hold	$105.00	24.84% Upside
NVO Novo Nordisk A/S	2.50	Moderate Buy	$76.00	34.00% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, DSNKY, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2025	NVO Novo Nordisk A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$50.00 ➝ $55.00
10/14/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/14/2025	NVO Novo Nordisk A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
10/13/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$84.00 ➝ $95.00
10/10/2025	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$876.00 ➝ $879.00
10/9/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$925.00
10/8/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$875.00 ➝ $948.00
10/8/2025	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
10/8/2025	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/3/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,028.00 ➝ $1,023.00
10/1/2025	NVO Novo Nordisk A/S	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$70.00

(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	4.08	$1.28 per share	20.87	$5.61 per share	4.75
LLY Eli Lilly and Company	$53.26B	14.68	$14.35 per share	57.56	$15.03 per share	54.97
MRK Merck & Co., Inc.	$64.17B	3.27	$9.29 per share	9.05	$18.33 per share	4.59
NVO Novo Nordisk A/S	$42.12B	6.01	$3.85 per share	14.74	$4.66 per share	12.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.06	25.16	24.47	1.25	15.40%	18.39%	8.57%	10/31/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	54.00	26.55	1.17	25.91%	92.72%	16.89%	10/30/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	12.96	8.50	0.94	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	15.58	12.17	2.60	35.60%	78.64%	24.51%	11/5/2025 (Estimated)

Latest LLY, NVO, DSNKY, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2025	Q3 2025	NVO Novo Nordisk A/S	$0.90	N/A	N/A	N/A	$11.98 billion	N/A
10/30/2025	Q3 2025	LLY Eli Lilly and Company	$6.42	N/A	N/A	N/A	$16.09 billion	N/A
10/30/2025	Q3 2025	MRK Merck & Co., Inc.	$2.37	N/A	N/A	N/A	$17.00 billion	N/A
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	$0.29	1.09%	N/A	27.36%	N/A
LLY Eli Lilly and Company	$6.00	0.73%	N/A	39.22%	11 Years
MRK Merck & Co., Inc.	$3.24	3.85%	N/A	49.92%	14 Years
NVO Novo Nordisk A/S	$0.82	1.45%	N/A	22.53%	N/A

Latest LLY, NVO, DSNKY, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4%	9/15/2025	9/15/2025	10/7/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.31	1.60
LLY Eli Lilly and Company	1.86	1.28	1.00
MRK Merck & Co., Inc.	0.69	1.42	1.17
NVO Novo Nordisk A/S	0.52	0.78	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.09%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.50 billion	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable

LLY, NVO, DSNKY, and MRK Headlines

Recent News About These Companies

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

...

1 hour ago | marketbeat.com

Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?

October 15 at 9:41 AM | zacks.com

Novo Nordisk begins round of layoffs in United States, sources say

October 15 at 9:39 AM | reuters.com

Novo Nordisk pens $2.1B deal for Omeros’ stalled PNH drug

October 15 at 9:35 AM | fiercebiotech.comF

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

October 15 at 9:17 AM | wsj.com

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

October 15 at 8:32 AM | reuters.com

BMO Capital Maintains Novo Nordisk A (NVO) Market Perform Recommendation

October 15 at 4:34 AM | msn.com

Cwm LLC Increases Stock Holdings in Novo Nordisk A/S $NVO

October 15 at 4:13 AM | marketbeat.com

Meet the 1.4% Yield Dividend Stock That Could Soar in 2026

October 15 at 4:00 AM | fool.com

Novo Nordisk A/S $NVO Shares Sold by Aberdeen Group plc

October 15 at 3:42 AM | marketbeat.com

Focus: Inside Novo Nordisk's 'Club 5,000' as Danish staff cuts gain pace

October 15 at 2:06 AM | reuters.com

Novo Nordisk A/S (NYSE:NVO) Shares Down 1.4% - Time to Sell?

October 14 at 5:40 PM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Given Hold (C) Rating at Weiss Ratings

October 14 at 2:42 PM | marketbeat.com

Analysts Think These Stocks Could More Than Double in Value (NVO)

...

October 14 at 11:54 AM | marketbeat.com

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

October 14 at 10:00 AM | zacks.com

Equitable Trust Co. Sells 18,042 Shares of Novo Nordisk A/S $NVO

October 14 at 7:30 AM | marketbeat.com

Novo Nordisk A/S $NVO Shares Acquired by Naviter Wealth LLC

October 14 at 6:36 AM | marketbeat.com

Elefante Mark B Has $1.14 Million Stock Holdings in Novo Nordisk A/S $NVO

October 14 at 6:15 AM | marketbeat.com

Novo Nordisk A/S $NVO Shares Bought by MGO One Seven LLC

October 14 at 4:55 AM | marketbeat.com

Novo Nordisk A/S $NVO Stake Increased by Concurrent Investment Advisors LLC

October 14 at 4:24 AM | marketbeat.com

Johnson Investment Counsel Inc. Purchases 4,511 Shares of Novo Nordisk A/S $NVO

October 14 at 4:24 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, NVO, DSNKY, and MRK Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$26.67 +0.92 (+3.57%)

As of 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Eli Lilly and Company NYSE:LLY

$826.20 +13.85 (+1.71%)

Closing price 03:59 PM Eastern

Extended Trading

$826.00 -0.20 (-0.02%)

As of 05:13 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$84.11 -0.59 (-0.70%)

Closing price 03:59 PM Eastern

Extended Trading

$84.23 +0.12 (+0.14%)

As of 05:10 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$56.72 +0.06 (+0.10%)

Closing price 03:59 PM Eastern

Extended Trading

$56.78 +0.06 (+0.11%)

As of 05:12 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, NVO, DSNKY, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, NVO, DSNKY, and MRK Earnings

Compare Dividends

Latest LLY, NVO, DSNKY, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, NVO, DSNKY, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, NVO, DSNKY, and MRK Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools